

PharmLabs San Diego Certificate of Analysis



Sample CAPS - FIZZY TABLETS - STRAWBERRY

Delta9 THC ND THCa ND Total THC (THCa \* 0.877 + THC) ND Delta8 THC ND

Sample ID SD250929-058 (124017)	Matrix Edible
Tested for CAPS	
Sampled - Received Sep 29, 2025	Reported Oct 03, 2025
Analyses executed CANX, 4AD, TRY, PSY, PRY	Unit Mass (g) 1.57 Num. of Servings 2 Serving Size (g) 0.79

CANx - Cannabinoids

Analyzed Oct 02, 2025 | Instrument HPLC-VWD | Method SOP-001  
 The expanded Uncertainty of the Cannabinoids analysis is approximately ±7.81% at the 95% Confidence Level

Analyte	LOD mg/g	LOQ mg/g	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THCV)	0.013	0.041	ND	ND	ND	ND
Cannabidiol (CBDO)	0.006	0.02	ND	ND	ND	ND
Abnormal Cannabidiol (a-CBDO)	0.013	0.038	ND	ND	ND	ND
(+/-)-9B-Hydroxy-Hexahydrocannabinol (9b-HHC)	0.015	0.045	ND	ND	ND	ND
11-Hydroxy-Δ8-Tetrahydrocannabinol (11-Hyd-Δ8-THC)	0.015	0.045	ND	ND	ND	ND
Cannabidiolic Acid (CBDA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol Acid (CBGA)	0.033	0.16	ND	ND	ND	ND
Cannabigerol (CBG)	0.048	0.16	ND	ND	ND	ND
Cannabidiol (CBD)	0.069	0.229	ND	ND	ND	ND
1(S)-Tetrahydrocannabinol (1(S)-H4-CBD)	0.008	0.026	ND	ND	ND	ND
1(R)-Tetrahydrocannabinol (1(R)-H4-CBD)	0.016	0.049	ND	ND	ND	ND
Tetrahydrocannabinol (THCV)	0.049	0.162	ND	ND	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THCV)	0.012	0.036	ND	ND	ND	ND
Cannabidiol (CBDH)	0.014	0.042	ND	ND	ND	ND
Tetrahydrocannabinol (Δ9-THCB)	0.01	0.029	ND	ND	ND	ND
Cannabinol (CBN)	0.047	0.16	ND	ND	ND	ND
Cannabidiophorol (CBDP)	0.016	0.049	ND	ND	ND	ND
exo-THC (exo-THC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinol (Δ9-THC)	0.092	0.307	ND	ND	ND	ND
Δ8-tetrahydrocannabinol (Δ8-THC)	0.044	0.16	ND	ND	ND	ND
(6aR,9S)-Δ10-Tetrahydrocannabinol ((6aR,9S)-Δ10)	0.015	0.8	ND	ND	ND	ND
Hexahydrocannabinol (S Isomer) (9s-HHC)	0.017	0.8	ND	ND	ND	ND
(6aR,9R)-Δ10-Tetrahydrocannabinol ((6aR,9R)-Δ10)	0.007	0.8	ND	ND	ND	ND
Hexahydrocannabinol (R Isomer) (9r-HHC)	0.016	0.8	ND	ND	ND	ND
Tetrahydrocannabinolic Acid (THCA)	0.117	0.389	ND	ND	ND	ND
Δ9-Tetrahydrocannabinol (Δ9-THCH)	0.02	0.061	ND	ND	ND	ND
Cannabinol Acetate (CBNO)	0.009	0.027	ND	ND	ND	ND
9(S)-Hexahydrocannabinolic Acid (9(S)-HHCa)	0.063	0.065	ND	ND	ND	ND
9(R)-Hexahydrocannabinolic Acid (9(R)-HHCa)	0.191	0.196	ND	ND	ND	ND
Δ9-Tetrahydrocannabinol (Δ9-THCP)	0.017	0.8	ND	ND	ND	ND
Δ8-Tetrahydrocannabinol (Δ8-THCP)	0.041	0.8	ND	ND	ND	ND
Cannabicitran (CBT)	0.005	0.16	ND	ND	ND	ND
Δ8-THC-O-acetate (Δ8-THCO)	0.076	0.8	ND	ND	ND	ND
9(S)-HHCP (s-HHCP)	0.013	0.041	ND	ND	ND	ND
Δ9-THC-O-acetate (Δ9-THCO)	0.066	0.8	ND	ND	ND	ND
9(R)-HHCP (r-HHCP)	0.015	0.045	ND	ND	ND	ND
9(S)-HHC-O-acetate (s-HHCO)	0.037	0.112	ND	ND	ND	ND
9(R)-HHC-O-acetate (r-HHCO)	0.031	0.093	ND	ND	ND	ND
3-octyl-Δ8-Tetrahydrocannabinol (Δ8-THC-C8)	0.021	0.062	ND	ND	ND	ND
Total THC (THCa * 0.877 + Δ9THC)			ND	ND	ND	ND
Total THC + Δ8THC + Δ10THC (THCa * 0.877 + Δ9THC + Δ8THC + Δ10THC)			ND	ND	ND	ND
Total CBD (CBDA * 0.877 + CBD)			ND	ND	ND	ND
Total CBG (CBGa * 0.877 + CBG)			ND	ND	ND	ND
Total HHC (9r-HHC + 9s-HHC)			ND	ND	ND	ND
Total Cannabinoids Analyzed			ND	ND	ND	ND

4AD - 4AD Tryptamines

Analyzed Sep 30, 2025 | Instrument HPLC VWD | Method SOP-4AD  
 The expanded Uncertainty of the 4AD Tryptamines analysis is approximately ±7.806% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Mescaline (MESc)	0.19	0.584	ND	ND	ND	ND
N,N-Dimethyltryptamine (DMT)	0.015	0.048	ND	ND	ND	ND
Psilocybin (PSLA)	0.015	0.044	ND	ND	ND	ND
4-Hydroxy-DET (4HDE)	0.014	0.042	ND	ND	ND	ND
4-Acetoxy-MET (4AME)	0.018	0.053	ND	ND	ND	ND
4-Acetoxy-DET (4ADE)	0.004	0.011	0.07	0.72	0.57	1.13
4-Bromo-DMP (2C-B)	0.19	0.576	ND	ND	ND	ND
Total Analyzed	-	-	0.07	0.72	0.57	1.13

UI Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
 Fri, 03 Oct 2025 11:32:33 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2019 Form B91. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.

TRY - Tryptamine

Analyzed Oct 01, 2025 | Instrument HPLC VWD | Method SOP-TRY

The expanded Uncertainty of the Tryptamine analysis is approximately ±7.806% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Norbaeocystin (NORB)	0.01	0.029	ND	ND	ND	ND
Baeocystin (BAEO)	0.01	0.029	ND	ND	ND	ND
Aeruginascin (AERU)	0.007	0.022	ND	ND	ND	ND
Norpsilocin (NORP)	0.003	0.009	ND	ND	ND	ND

PSY - Psilocybin & Psilocin

Analyzed Sep 30, 2025 | Instrument HPLC VWD | Method SOP-PSY

The expanded Uncertainty of the Psilocybin & Psilocin analysis is approximately ±7.806% at the 95% Confidence Level

Analyte	LOD ppm	LOQ ppm	Result %	Result mg/g	Result mg/Serving	Result mg/Unit
Psilocybin (PSCY)	0.007	0.019	ND	ND	ND	ND
Psilocin (PSCI)	0.003	0.009	ND	ND	ND	ND

UI Unidentified  
 ND Not Detected  
 N/A Not Applicable  
 NT Not Reported  
 LOD Limit of Detection  
 LOQ Limit of Quantification  
 <LOQ Detected  
 >ULOL Above upper limit of linearity  
 CFU/g Colony Forming Units per 1 gram  
 TNTC Too Numerous to Count



DEA license: RP0611043  
 ISO/IEC 17025:2017 Acc. 85368



Scan the QR code to verify authenticity.

Authorized Signature

*Brandon Starr*

Brandon Starr, Quality Assurance Manager  
 Fri, 03 Oct 2025 11:32:33 -0700

PharmLabs San Diego | 3421 Hancock St, Second Floor, San Diego, CA 92110 | 619.356.0898 | ISO/IEC 17025:2017 Acc. 85368



PharmLabs hereby states that its Certificates of Analysis (COA) do not certify compliance with any federal, state, or local law or regulation, including but not limited to the 2019 Farm Bill. This COA is provided solely for informational purposes and is not intended for reliance by consumers or purchasers of a product. This report shall not be reproduced, except in full, without the prior written approval of PharmLabs. This report is not intended to diagnose, treat, cure, or prevent any disease. Results apply only to the specific sample(s) and batch(es) identified on this COA and do not represent any other lot, batch, or product from the client. Measurement of uncertainty is available upon request and, when legally required, has been reported on the certificate. PharmLabs makes no representation or warranty, express or implied, regarding the tested product's safety, efficacy, quality, merchantability, or fitness for a particular purpose. PharmLabs expressly disclaims any liability for damages, claims, costs, or expenses arising out of the use, misuse, or reliance upon this COA by any party. PharmLabs relies on information provided by the client regarding the identity, sampling, and chain of custody of the submitted material. PharmLabs assumes no responsibility for errors, omissions, or misrepresentations in such information. It is the sole responsibility of the client to determine and ensure the compliance of their product(s) with all applicable federal, state, and local laws and regulations. This COA may not be used in whole or in part for marketing, advertising, promotional, or labeling purposes without the prior written consent of PharmLabs. This COA is valid only as of the date of issuance and does not guarantee the stability or continued conformity of the tested product beyond that date. Any dispute arising out of or related to this COA shall be governed by the laws of the State of California, without regard to its conflict of laws principles.